Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kanungo, Suman ^a   Lopez, Anna Lena ^b   Ali, Mohammad ^c   Manna, Byomkesh ^a   Kim, Deok Ryon ^c   Mahapatra, Tanmay ^a   Holmgren, Jan ^d   Dhingra, Mandeep S ^e   Weirzba, Thomas F ^c   Nair, G Balakrish ^f   Bhattacharya, Sujit K ^g   Clemens, John D ^h   Sur, Dipika ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c International Vaccine Institute   (South Korea)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Shantha Biotechnics Limited   (India)

^f Translational Health Science and Technology Institute   (India)

^g NATIONAL ACADEMY OF SCIENCES   (India)

^h INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHOLERA VACCINE; PLACEBO;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CHILD; CHOLERA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INDIA; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIBRIO CHOLERAE; ADULT; ANTIBODY PRODUCTION; CLINICAL TRIAL; IMMUNOLOGY; INFANT; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PROCEDURES;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; DOUBLE-BLIND METHOD; HUMANS; INDIA; INFANT; VACCINATION; VIBRIO CHOLERAE;

EID: 84900453838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096499     Document Type: Article

References (21)

1. Global Alert and Response (GAR): Cholera. WHO.
2. Thiem VD, Deen JL, Von Seidlein L, Canh DG, Anh DD, et al. (2006) Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24: 4297-4303.
3. Trach D, Clemens J, Ke N, Thuy H, Son N, et al. (1997) Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349: 231-235. (Pubitemid 27050988)
4. (2004) WHO Expert Committee on Biological Standardization : fifty-second report. Technical report series (World Health Organization), 924.
5. Anh DD, Canh do G, Lopez AL, Thiem VD, Long PT, et al. (2007) Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25: 1149-1155.
6. Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, et al. (2008) A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3: e2323.
7. Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, et al. (1997) Vibriocidal antibody responses in North American volunteers exposed to wildtype or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol 4: 264-269. (Pubitemid 27239682)
8. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, et al. (2004) Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis 189: 2318-2322. (Pubitemid 38757206)
9. Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
10. Bhattacharya S, Sur D, Ali M, Kanungo S, You Y, et al. Five-year efficacy of a bivalent killed whole-cell oral cholera vaccine against cholera among residents of Kolkata, India. N Engl J Med (submitted).
11. Sur D, Kanungo S, Sah B, Manna B, Ali M, et al. (2011) Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 5: e1289.
12. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, et al. (2009) Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. The Lancet 374: 1694-1702.
13. Jertborn M, Svennerholm A-M, Holmgren J (1994) Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12: 1078-1082.
14. Attridge SR, Johansson C, Trach DD, Qadri F, Svennerholm A-M (2002) Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139. Clin Diagn Lab Immunol 9: 383-387. (Pubitemid 34226036)
15. Sack D, Clemens J, Huda S, Harris J, Khan M, et al. (1991) Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 164: 407-411.
16. Begue RE, Castellares G, Cabezas C, Sanchez JL, Meza R, et al. (1995) Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit. Infect Immun 63: 3726-3728.
17. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castaneda E, et al. (1994) Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12: 1000-1003. (Pubitemid 24246871)
18. Jertborn M, Svennerholm AM, Holmgren J (1988) Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. J Infect Dis 157: 374-377. (Pubitemid 18061255)
19. Lycke N, Hellstrom U, Holmgren J (1987) Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scand J Immunol 26: 207-211.
20. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, et al. (2011) Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 8285-8292.
21. (2010) Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85: 117-128.